EP3151812A1 - Particules d'inhalation comprenant une combinaison d'un anticholinergique, d'un corticostéroïde et d'un bêta-adrénergique - Google Patents

Particules d'inhalation comprenant une combinaison d'un anticholinergique, d'un corticostéroïde et d'un bêta-adrénergique

Info

Publication number
EP3151812A1
EP3151812A1 EP15731264.6A EP15731264A EP3151812A1 EP 3151812 A1 EP3151812 A1 EP 3151812A1 EP 15731264 A EP15731264 A EP 15731264A EP 3151812 A1 EP3151812 A1 EP 3151812A1
Authority
EP
European Patent Office
Prior art keywords
microparticles
active ingredients
formulation
particles
micron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15731264.6A
Other languages
German (de)
English (en)
Other versions
EP3151812B1 (fr
Inventor
Michele MIOZZI
Timothy J ROUSE
Gaetano Brambilla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to PL15731264T priority Critical patent/PL3151812T3/pl
Publication of EP3151812A1 publication Critical patent/EP3151812A1/fr
Application granted granted Critical
Publication of EP3151812B1 publication Critical patent/EP3151812B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Definitions

  • the present invention relates to particles comprising three active ingredients for administration by inhalation.
  • the invention relates to particles comprising a combination of an anticholinergic, a beta2-adrenoceptor agonist, and an inhaled corticosteroid, process for their preparation and use thereof for the prevention and/or treatment of respiratory diseases.
  • Respiratory diseases are a common and important cause of illness and death around the world.
  • many people are affected by inflammatory and/or obstructive lung diseases, a category characterized by inflamed and easily collapsible airways, obstruction to airflow, problems exhaling and frequent medical clinic visits and hospitalizations.
  • Types of inflammatory and/or obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • bronchodilators such as p 2 -agonists and anticholinergics are the mainstay of symptom management in mild and moderate disease, prescribed on an as-needed basis for mild COPD and as a maintenance therapy for moderate COPD.
  • Said bronchodilators are efficiently administered by inhalation, thus increasing the therapeutic index and reducing side effects of the active material.
  • ICSs inhaled corticosteroids
  • LPA long-acting p 2 -agonist
  • FF dihydrate fumarate salt
  • GB rac-glycopyrronium bromide
  • BDP beclometasone dipropionate
  • WO 02/28377 disclose particles incorporating, inter alia, a LABA and an ICS.
  • the invention is directed to multicomponent microparticles for use in a formulation for inhalation, each microparticle comprising a combination of beclometasone dipropionate, a pharmaceutically acceptable salt of formoterol, and a pharmaceutically acceptable salt of glycopyrronium in a ratio comprised between 35: 10:55 and 94: 1 :5 w/w/w, whereby said microparticles are characterized by a shape factor comprised between 0.8 and 1.15, preferably between 0.9 and 1.10, more preferably between 0.95 and 1.05.
  • microparticles have a volume diameter equal to or lower than 4.5 micron, preferably equal to or lower than 4.0 micron, and the volume median diameter of said microparticles is comprised between 1.0 and 3.0 micron, preferably 1.2 and 2.5 micron, more preferably between 1.5 and 2.2 micron.
  • the invention provides pharmaceutical aerosol formulations for pressurized metered dose inhalers (pMDIs) comprising the above microparticles in suspension in a liquefied propellant gas.
  • pMDIs pressurized metered dose inhalers
  • the invention provides a pressurized metered dose inhaler (pMDI) comprising a canister filled with the aforementioned pharmaceutical aerosol formulation, and a metering valve for delivering a daily therapeutically effective dose of the active ingredient.
  • pMDI pressurized metered dose inhaler
  • the invention concerns a dry powder pharmaceutical formulation comprising the above microparticles and, optionally a carrier.
  • the invention provides a dry powder inhaler filled with the aforementioned dry powder formulation.
  • the invention is directed to a process for preparing the claimed microparticles, the process comprising the steps of:
  • the invention refers to the claimed microparticles for use in the prevention and/or treatment of an inflammatory and/or obstructive airways disease such as asthma or chronic obstructive pulmonary disease (COPD).
  • an inflammatory and/or obstructive airways disease such as asthma or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the invention refers to a method of preventing and/or treating an inflammatory and/or obstructive airways disease, such as asthma or chronic obstructive pulmonary disease (COPD), which comprises administering by inhalation of an effective amount of the microparticles of the invention.
  • an inflammatory and/or obstructive airways disease such as asthma or chronic obstructive pulmonary disease (COPD)
  • COPD chronic obstructive pulmonary disease
  • the invention refers to the use of the claimed microparticles in the manufacture of a medicament for the prevention and/or treatment of an inflammatory and/or obstructive airways disease such as asthma or chronic obstructive pulmonary disease (COPD).
  • an inflammatory and/or obstructive airways disease such as asthma or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the invention refers to multicomponent microparticles for use in a formulation for inhalation comprising a combination of beclometasone dipropionate, a pharmaceutically acceptable salt of formoterol, and a pharmaceutically acceptable salt of glycopyrronium in a ratio comprised between 35: 10:55 and 94: 1 :5 w/w/w, whereby said microparticles are characterized by a shape factor comprised between 0.95 and 1.05 and are obtainable by a process comprising the steps of:
  • musclecarinic receptor antagonists antimuscarinic drugs
  • anticholinergic drugs can be used as synonymous.
  • glycopyrronium refers to a salt of the compound 3-[(cyclopentylhydroxyphenylacetyl)oxy]-l,l- dimethylpyrrolidinium.
  • pharmaceutically acceptable salt of formoterol refers to a salt of the compound 2'-hydroxy-5 '-[( S)- 1 -hydroxy-2- ⁇ [(RS)-p-methoxy-a- methylphenethyl] amino ⁇ ethyl] formanilide.
  • beclometasone dipropionate refers to the compound
  • pharmaceutically acceptable salt comprises inorganic and organic salts.
  • organic salts may include formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, methane sulfonate, benzenesulfonate, xinafoate, pamoate, and benzoate.
  • inorganic salts may include fluoride chloride, bromide, iodide, phosphate, nitrate and sulphate.
  • solvent is used to mean the medium in which the active ingredients are dissolved, while the term “anti-solvent” is used to mean the medium in which crystallization takes place.
  • multicomponent particle refers to the smallest discrete single particle comprising a combination of three active ingredients. Said single particle is engineered in spherical form.
  • micronized refers to a substance having a size of few microns.
  • centroid refers to a substance having a size of one or few hundred microns.
  • particle size of particles is quantified by measuring a characteristic equivalent sphere diameter, known as volume diameter, by laser diffraction.
  • the particle size can also be quantified by measuring the mass diameter by means of suitable known instrument such as, for instance, the sieve analyser.
  • the volume diameter (VD) is related to the mass diameter (MD) by the density of the particles (assuming a size independent density for the particles).
  • the particle size of the active ingredients and of fraction of fine particles is expressed in terms of volume diameter, while that of the coarse particles is expressed in terms of mass diameter.
  • the particles have a normal (Gaussian) distribution which is defined in terms of the volume or mass median diameter (VMD or MMD) which corresponds to the volume or mass diameter of 50 percent by weight of the particles, and, optionally, in terms of volume or mass diameter of 10% and 90% of the particles, respectively.
  • VMD volume or mass median diameter
  • Another common approach to define the particle size distribution is to cite three values: i) the median diameter d(0.5) which is the diameter where 50% of the distribution is above and 50% is below; ii) d(0.9), where 90% of the distribution is below this value; iii) d(0.1), where 10% of the distribution is below this value.
  • the span is the width of the distribution based on the 10%, 50% and 90% quantile and is calculated according to the formula.
  • particles having the same or a similar VMD or MMD can have a different particle size distribution, and in particular a different width of the Gaussian distribution as represented by the d(0.1) and d(0.9) values.
  • the particle size is expressed as mass aerodynamic diameter (MAD), while the particle size distribution is expressed in terms of mass median aerodynamic diameter (MMAD) and Geometric Standard Deviation (GSD).
  • MAD mass aerodynamic diameter
  • MMAD mass median aerodynamic diameter
  • GSD Geometric Standard Deviation
  • the particle size of the microparticles of the invention can be determined by scanning electron microscopy according to methods known to the skilled person in the art.
  • the term 'interactive or ordered mixture' refers to powder formulation for inhalation comprising a pharmacologically-inert physiologically acceptable carrier substance, to which the micronised active compound particles are bonded by adhesion in order thus to achieve and to maintain a suitable mixed material, i.e. homogeneity of the mixture.
  • fissured surface means a surface on which there are clefts and valleys and other recessed regions, referred to herein collectively as fissures.
  • Said surface of the coarse excipient particles may be defined in terms of fissure index or rugosity coefficients as disclosed in WO 01/78695 and WO 01/78693 and they can be characterized according to the description therein reported.
  • 'hard pellets' refers to spherical or semispherical units whose core is made of coarse excipient particles.
  • the term 'good flowability' refers to a formulation that is easy handled during the manufacturing process and is able to ensure an accurate and reproducible delivering of the therapeutically effective dose.
  • Flow characteristics can be evaluated by different tests such as angle of repose, Carr's index, Hausner ratio or flow rate through an orifice.
  • the expression 'good homogeneity' refers to a powder wherein, upon mixing, the uniformity of distribution of a component, expressed as coefficient of variation (CV) also known as relative standard deviation (RSD), is less than 5.0%. It is usually determined according to known methods, for instance by taking samples from different parts of the powder and testing the component by HPLC or other equivalent analytical methods such as UPLC.
  • CV coefficient of variation
  • RSD relative standard deviation
  • the expression 'respirable fraction' refers to an index of the percentage of the active ingredient particles which would reach the lungs in a patient.
  • the respirable fraction is evaluated using a suitable in vitro apparatus such as Andersen Cascade Impactor (ACI), Multi Stage Liquid Impinger (MLSI) or Next Generation Impactor (NGI), according to procedures reported in common Pharmacopoeias, in particular in the European Pharmacopeia (Eur. Ph.) 7.3, 7 th Edition.
  • ACI Andersen Cascade Impactor
  • MLSI Multi Stage Liquid Impinger
  • NBI Next Generation Impactor
  • the delivered dose is calculated from the cumulative deposition in the apparatus, while the fine particle mass is calculated from the deposition of particles having a diameter ⁇ 5.0 micron.
  • the formulation is defined as extrafme formulation when it is able of delivering a fraction of particles having a particle size equal or less than 2.0 micron equal to or higher than 20%, preferably equal to or higher than 25%, more preferably equal to or higher than 30% and/or it is able of delivering a fraction of particles having a particle size equal or less than
  • ⁇ 1.0 micron equal to or higher than 10%, preferably equal to or higher than 20%.
  • the expression 'chemically stable' refers to an active ingredient that, upon storage of the microparticles, meets the requirements of the EMEA Guideline CPMP/QWP/ 122/02 referring to 'Stability Testing of Existing Active Substances and Related Finished Products'.
  • the expression 'physically stable' refers to microparticles which exhibit substantially no change in morphology, no transition from amorphous to crystalline state or vice versa, no growth in particle size during storage for at least one month at room temperature and 60% relative humidity, as determined according to methods known to the skilled person in the art.
  • the expression 'good constancy of the active ingredients ratio' means that the three active ingredients, after delivery of a single therapeutic dose, maintain substantially the same ratio as the pre-determined ratio of said two active ingredient in the formulation, i.e. that the relative standard deviation (RSD) of the ratio of the amounts of drugs measured in an vitro apparatus such as NGI is less is less than 15%, preferably less than 10%.
  • RSD relative standard deviation
  • the term 'prevention' means an approach for reducing the risk of onset of a disease.
  • treatment means an approach for obtaining beneficial or desired results, including clinical results.
  • beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i. e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
  • the term can also mean prolonging survival as compared to expected survival if not receiving treatment.
  • 'severe persistent asthma' is defined as a form characterized by daily symptoms, frequent exacerbations, frequent nocturnal asthma symptoms, limitation of physical activities, forced expiratory volume in one second (FEVi) equal to or less than 60% predicted and with a variability higher than 30%.
  • FEVi forced expiratory volume in one second
  • COPD' chronic Obstructive Pulmonary Disease
  • FVC Forced Vital Capacity
  • the expression 'single therapeutically effective dose' means the quantity of active ingredient administered at one time by inhalation upon actuation of the inhaler. Said dose may be delivered in one or more actuations, preferably one actuation (shot) of the inhaler.
  • 'Actuation' refers to the release of active ingredients from the device by a single activation (e.g. mechanical or breath).
  • 'UPLC-PDA' refers to a Ultra Performance Liquid Chromatography instrument coupled with a Photodiode Array detector.
  • Figure 1 SEM micrographs of the microparticle s of the invention obtained by spray-drying.
  • the invention is directed to multicomponent microparticles for use in a formulation for inhalation, each microparticle comprising a combination of beclometasone dipropionate, a pharmaceutically acceptable salt of formoterol, and a pharmaceutically acceptable salt of glycopyrronium.
  • Formoterol may be present in form of any pharmaceutically acceptable salts and/or solvate form thereof, preferably in form of dihydrate fumarate salt.
  • Glycopyrronium may be used in the form of any of the pure enantiomers or diastereoisomers or any combination thereof in practicing the present invention.
  • the (3S,2' ), (3R,2'S) 1 : 1 racemic mixture is used, also known as rac-glycopyrronium.
  • Said active ingredient may be present in form of any pharmaceutically acceptable salts and/or solvate form thereof, preferably in form of bromide or monohydrate chloride, more preferably in form of bromide salt.
  • Beclometasone dipropionate may be anhydrous or present in form of monohydrate.
  • each microparticle consists of a combination of formoterol fumarate or its dihydrate form thereof, glycopyrronium bromide and beclometasone dipropionate.
  • the ratio by weight in which the three active ingredients, e.g. beclometasone dipropionate, a pharmaceutically acceptable salt of formoterol, and a pharmaceutically acceptable salt of glycopyrronium, are present in the microparticles is pre-determined in such a way as to deliver the desired single therapeutically effective dose of each active ingredient.
  • the ratio by weight among the three active ingredients is given by making reference to the anhydrous form of beclometasone dipropionate (BDP), to the dihydrate fumarate salt of formoterol (FF), and to the bromide salt of glycopyrronium (GB).
  • BDP beclometasone dipropionate
  • FF dihydrate fumarate salt of formoterol
  • GB bromide salt of glycopyrronium
  • ratio could be comprised between 35: 10:55 and 94: 1 :5 w/w/w. In a preferred embodiment the ratio could be comprised between 70: 10:20 to 92:2:6.
  • ratios according to the invention are: 84.4:5.1 : 10.5 w/w/w to deliver 100 microg BDP, 6 microg FF, and 12.5 microg GB; 91.5:2.7:5.7 w/w/w to deliver 200 microg BDP, 6 microg FF, and 12.5 GB; 73.0:8.8: 18.2 w/w/w to deliver 50 microg BDP, 6 microg FF, and 12.5 GB; 80.3: 9.6: 10.1 w/w/w to deliver 100 microg BDP, 12 microg FF, and 12.5 microg GB; 89.1 : 5.3:5.6 w/w/w to deliver 200 microg BDP, 12 microg FF, and 12.5 microg GB; 72.7:4.4:22.9 to deliver 200 microg BDP, 12 microg FF and 63 microg GB; 59.2:3.5:37.3 w/w/w to deliver 100 microg BDP, 6 microg FF, and 63 microg GB, 7
  • the three active ingredients could be present in a ratio of 84.4:5.1 : 10.5, or 91.5:2.7:5.7 or 73.0:8.8: 18.2 w/w/w, more preferably of 84.4:5.1 : 10.5 w/w/w.
  • microparticles of the invention Upon preparation, the microparticles of the invention turned out be chemically stable.
  • microparticles of the invention have a uniform and regular spherical shape exhibiting more homogeneous forces of adhesion along the whole powder which are in turn associated with the improved DPI performances.
  • the shape factor is used to characterize the shape of the microparticles.
  • microparticles of the invention are characterized by a shape factor comprised between 0.8 and 1.15, preferably between 0.9 and 1.10, more preferably between 0.95 and 1.05.
  • the shape factor could be determined according to the following equation reported in Kumar S et al Curr Appl. Phys. Influence of metal powder shape on drag coefficient in a spray jet, 2009, 9, 678-682
  • N indicates the roundness of the particle and is calculated by applying the following formula:
  • p and A are the mean perimeter and area values, respectively, of at least ten spherical particles as measured from Scanning electron microscopy (SEM) images.
  • the mean perimeter and area may be measured by an optical microscope.
  • Scanning electron microscopy (SEM) or optical microscopy may also be used to qualitatively appreciate the characteristics of the powder particles of the invention such as particles shape and their surface morphology.
  • microparticles of the invention should be administered to the lungs by inhalation, at least 90% of them should have a volume diameter equal to or lower than 6 micron.
  • microparticles of the invention all the three active ingredients could simultaneously reach the distal tract of the respiratory tree whereby they could act synergistically and improve small airways outcomes and associated control.
  • said microparticles are characterized by a selected, narrow, and well defined particle size distribution wherein the at least 90% of all of them have a volume diameter lower than 4.5 micron, preferably equal to or lower than 4.0 micron, and their volume median diameter is comprised between 1.0 and 3.0 micron, more advantageously between 1.2 and 2.5 micron, preferably between 1.5 and 2.2 micron.
  • no more than 10% of said microparticles have a volume diameter lower than 0.2 micron, preferably equal to or lower than 0.5 micron, more preferably equal to or lower than 0.6 micron.
  • the width of the particle size distribution of the particles of each active ingredient should be advantageously comprised between 1.0 and 4.0, more advantageously between 1.2 and 3.5, preferably between 1.5 and 2.0. According the Chew et al J Pharm Pharmaceut Sci 2002, 5, 162-168, the span corresponds to [d (v, 0.9) - d(v,0.1)]/d(v,0.5).
  • the size of the particles active is determined by measuring the characteristic equivalent sphere diameter, known as volume diameter, by laser diffraction.
  • volume diameter the characteristic equivalent sphere diameter
  • the volume diameter has been determined using a Malvern apparatus.
  • other equivalent apparatus may be used by the skilled person in the art.
  • the Specific Surface Area of the microparticles of the invention shall be comprised between 1.5 and 3.5 m 2 /g, preferably between 2.0 and 3.0 m 2 /g, preferably between 2.2 and 2.8 m 2 /g.
  • the cohesion and adhesion forces of the microparticles of the invention were also assessed by atomic force microscopy (AFM) according to the experimental procedure reported in Example 2.
  • a bed of alpha-lactose monohydrate powder was used to perform the measurements. This powder bed represents a heterogeneous surface in which the contact area for adhesion is highly variable. The contact area in turn is a dominant factor in determining the force of interaction.
  • Comparison of the obtained adhesion and cohesion forces suggests that there is no statistical difference in the magnitude of the interaction of the microparticles of the invention with themselves or with the lactose powder.
  • common micronised active ingredients are either strongly adhesive or cohesive.
  • the microparticles of the invention may exhibit improved dispersion when formulated as interactive ordered mixtures with excipient particles of lactose as a carrier. In fact, they would be less prone to give rise to the formation of stable agglomerates like common micronised active ingredients.
  • the present invention provides a process for the production of the microparticles of the invention comprising the steps of:
  • the microparticles are obtained as a completely amorphous powder in that each active ingredients is present in an amorphous form.
  • the choice of the solvent is critical as, besides having a high solubilising capacity for the three active ingredients, it should have a suitable degree of volatility and diffusion characteristics within the atomized droplets. These properties indeed significantly affect the particle size distribution of the resulting microparticles.
  • the solvent could be selected from the group consisting of methanol, ethanol, water, DMSO, acetonitrile and mixtures thereof.
  • the solvent is a mixture of ethanol: water ranging from 85 : 15 to 95:5 v/v, preferably 90: 10 v/v.
  • any aerosol based atomisation system could be used for generation of the aerosol.
  • Various systems for generating aerosols are well-known.
  • the aerosol may, for example, be generated from the desired substance dissolved in a suitable solvent by electrohydrodynamic spraying, high air pressure atomiser or other aerosol generators including pneumatic systems, rotary (spinning-top) systems, spray nozzles, nebulizers, propellant evaporation systems, piezoelectric transducers and ultrasonic transducers.
  • the microparticles are prepared by spray-drying.
  • the solution of step a) is introduced into the drying chamber of a spray-drier through an atomizing device to form droplets and the atomized droplets are dried by introducing a stream of pre -heated drying gas into said drying chamber.
  • the skilled person in the art shall properly adjust the conditions of the aerosol generation such as the temperature of the solution, the solution flow rate and the pressure of the carrier gas in relation with the desired particle size distribution of the microparticles and the size of the batch.
  • step d) of the aforementioned process of preparation the microparticles are collected in a vessel containing an anti-solvent for all the three active ingredients; then a high intensity ultrasound is applied to change the morphology of the microparticles and induce the crystallization of at least one of the three active ingredients present in the microparticle. Finally the microparticles are isolated according to methods known to the skilled person in the art.
  • the anti-solvent may advantageously selected from the group consisting of n-heptane, cyclohexane, and fluorinated hydrocarbons such as perfluorodecalin.
  • the partially amorphous or crystalline microparticles could be further isolated and collected.
  • microparticles of the invention comprising formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide are isolated as an amorphous powder, they contain all the three active ingredients in the anhydrous form.
  • microparticles when isolated as partially amorphous or crystalline powder, they might contain formoterol fumarate as dihydrate form and beclometasone dipropionate as monohydrate form.
  • all the three active ingredient in the microparticles are in a crystalline form.
  • the extent of crystallinity expressed as weight % of the crystalline microparticle with respect to the total weight of the microparticle, is higher than 90%, preferably higher than 95%.
  • the amorphicity and/or crystallinity and extent thereof may be determined using X-ray powder diffraction or other techniques known to the skilled person such as differential scanning calorimetry (DSC) or microcalorimetry.
  • DSC differential scanning calorimetry
  • microcalorimetry microcalorimetry
  • the presence of all the active ingredients in the microparticles could be detected by methods known to the skilled person such as Raman spectroscopy and solid state CP-MAS 13 C NMR spectroscopy.
  • microparticles of the invention are physically stable upon storage for at least one month.
  • amorphous or partially amorphous microparticles further stabilisation of the amorphous state can be achieved with the aid of suitable excipients in the relevant pharmaceutical formulation for inhalation, for example mannitol, leucine, or trehalose.
  • suitable excipients in the relevant pharmaceutical formulation for inhalation for example mannitol, leucine, or trehalose.
  • the present invention provides a pharmaceutical formulation for administration by inhalation comprising the microparticles of the invention.
  • Said microparticles may be formulated together with one or more pharmaceutically acceptable excipients, additives, diluents or carriers.
  • the formulation may be provided in the form of suspension in a propellant as aerosol carrier to be administered by pressurized meted dose inhalers (pMDI).
  • pMDI pressurized meted dose inhalers
  • the pMDI comprises a canister wherein the formulation is filled and a metering valve for delivering a daily therapeutically effective dose of the formulation.
  • the aerosol carrier may consist of a non-chlorofluorocarbon-based propellant such as hydrofluoralkane (HFA).
  • HFA hydrofluoralkane
  • the propellants HFA 134a, and HFA 227 or mixtures thereof may be advantageously used.
  • the suspension formulation may comprise additional excipients such as surfactants, and wetting agents.
  • the formulation is provided in the form of dry powder for inhalation, more preferably in the form of an interactive or ordered mixture, by diluting the particles of the invention in a pharmacologically inert physiologically acceptable excipient consisting of coarser particles.
  • said powder formulation for inhalation may comprise the particles according to the invention and coarse particles of a physiologically acceptable excipient, e.g. particles having a MMD higher than 90 micron and preferably the MD comprised between 50 micron and 500 micron, more preferably between 150 and 400 micron, even more preferably between 210 and 355 micron.
  • the coarse particles have a MD comprised between 90 and 150 micron.
  • the coarse excipient particles when their MD is comprised between 210 and 355 micron, the coarse excipient particles have preferably a relatively highly fissured surface.
  • the aforementioned powder formulation may further comprise a fraction of particles having a MMD lower than 35 micron preferably lower than 15 micron, more preferably lower than 10 micron, composed of particles of a physiologically acceptable excipient and particles of an additive material selected from the class of the anti-adherents such as the amino acids leucine and isoleucine or of the lubricants such as magnesium stearate, sodium stearyl fumarate stearyl alcohol, stearic acid and sucrose monopalmitate (hereinafter the pre -blend fraction).
  • an additive material selected from the class of the anti-adherents such as the amino acids leucine and isoleucine or of the lubricants such as magnesium stearate, sodium stearyl fumarate stearyl alcohol, stearic acid and sucrose monopalmitate (hereinafter the pre -blend fraction).
  • the physiologically acceptable excipient may be constituted of any amorphous or crystalline physiologically acceptable pharmacologically-inert material of animal or vegetal source or combination thereof.
  • Preferred materials are crystalline sugars and for example monosaccharides such as glucose or arabinose, or disaccharides such as maltose, trehalose, saccharose, dextrose or lactose.
  • Polyalcohols such as mannitol, sorbitol, maltitol, lactitol may also be used.
  • the most preferred material is a-lactose monohydrate.
  • the pre -blend fraction is composed of 98% by weight of a-lactose monohydrate and 2% by weight of magnesium stearate and the ratio between the fraction of microparticles and the fraction of coarse particles made of a-lactose monohydrate particles is 10:90% by weight, respectively.
  • the amount of magnesium stearate in the final formulation is advantageously comprised between 0.02% and 1.0% by weight on the total weight of the formulation, preferably between 0.05 and 0.5% by weight, more preferably between 0.1 and 0.4% by weight, even more preferably between 0.2 and 0.3% by weight.
  • the powder formulation for inhalation comprising the microparticles according to the invention is endowed with good flowability properties and is characterized by a high degree of homogeneity.
  • the content uniformity of the active ingredient expressed as relative standard deviation ( SD), is less than 5%.
  • Said powder formulation may be administered by inhalation with any type of DPIs known in the art.
  • DPIs can be divided into two basic types: i) single dose inhalers, for the administration of pre-subdivided single doses of the active compound; ii) multidose dry powder inhalers (MDPIs), either with pre-subdivided single doses or pre-loaded with quantities of active ingredient sufficient for multiple doses.
  • MDPIs multidose dry powder inhalers
  • DPIs are divided in: i) low-resistance devices (> 90 1/min); ii) medium-resistance devices (about 60 1/min); iii) high-resistance devices (about 30 1/min).
  • the dry powder formulations comprising the microparticles of the invention are particularly suitable for multidose DPIs comprising a reservoir from which individual therapeutic dosages can be withdrawn on demand through actuation of the device, for example that described in WO 2004/012801.
  • Other multidose devices that may be used are, for instance, the DISKUSTM of GlaxoSmithKline, the TU BOHALE TM of AstraZeneca, the TWISTHALERTM of Schering and the CLICKHALERTM of Innovata.
  • the dry powder formulation is filled in the DPI device disclosed in WO 2004/012801, being particularly suitable for the delivery of extrafme formulation.
  • microparticles of the invention are indicated for the prevention and/or treatment of inflammatory or obstructive airways diseases such as asthma and chronic obstructive pulmonary disease (COPD).
  • inflammatory or obstructive airways diseases such as asthma and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the microparticles of the invention are particularly suitable for the prevention and/or treatment of severe and/or very severe forms of respiratory disorders, in particular severe and/or very severe COPD and severe persistent asthma.
  • the feedstock solution was spray dried using a B290 bench top spray dryer (Buchi) with a 2-fluid nozzle at a feed rate of 5g min "1 .
  • the cyclone and collection vessel were separated from the B290 spray dryer and stored for 24 hours at a temperature of 25°C and at a relative humidity of 20%.
  • microparticles as obtained in Example 1 were characterized in terms of drug content, particle size, morphology, physical state, cohesion/adhesion forces and specific surface area.
  • the particle size was determined by laser diffraction using an Rl lens (Sympatec HELOS). A sample of the powder was dispersed for two measurement conditions using an air pressure of 0.5 and 3 bar respectively (Sympatec RODOS) and sampled at a rate of 5m/s from a controlled temperature and humidity dosing unit (Sympatec ASPIROS). The average d[v,10], d[v,50], d[v,90] values were calculated from triplicate measurements.
  • the morphology of the microparticles was determined by scanning electron microscope (SEM) using Jeol JSM-6480LV instrument.
  • Samples were mounted on carbon tape and stored in a vacuum for 12 hours prior to analysis to prevent outgassing. Each sample was sputter coated with gold before imaging.
  • the shape factor analysis was performed as follows. A sample of spray dried powder was dispersed on a 10mm circular glass coverslip and coated with gold using an Agar sputter coater. SEM micrographs were obtained using a LEO1430VP instrument at an accelerating voltage of 10 kV and working distance of 10 mm. 120 SEM micrographs were acquired at 0° tilt and analyzed using Image Pro Analyser Version 7.0. The measurement parameters were set to acquire individual particles for shape analysis and any sampling anomalies i.e. selection of multiple particles, were removed manually.
  • Statistical analysis was performed on the RN and PSF data to determine whether sufficient particles had been analyzed to give consistent data.
  • the powder exhibited a uniform spherical morphology as demonstrated by SEM pictures ( Figure 1). Both the roundness (RN) and particle shape factor determined by image analysis of 3953 individual particles confirmed the spherical morphology of the particles (see Table 4).
  • XRPD was performed using a Bruker AXS D8 Advance, equipped with a Vantec-1 detector and using Cu K-alpha radiation (1.54 A).
  • the heat flow (W g "1 ) as a function of increasing temperature (°C) was determined using a TA Instruments Q2000 calorimeter. Samples were weighed into a non-hermetic aluminium DSC pan. The samples were equilibrated at 20°C before the temperature was ramped 5°C min "1 up to 220°C. The analysis was performed in triplicate and interpreted using Universal Analysis software.
  • Both DSC and X PD indicate that the material is amorphous.
  • the spray dried microparticles exhibited no peaks corresponding to short range order and crystalline structure and a typical amorphous halo is seen.
  • the force measuring capabilities of the atomic force microscope (AFM) were used to directly measure the adhesion forces between two surfaces.
  • Tipless contact mode AFM cantilevers (Bruker) with calibrated spring constant (typically 0.2-0.4 Nm "1 ) were used for all adhesion-cohesion measurements. Probes were prepared by attaching the microparticles to the tip of the cantilever, which was confirmed by optical and variable pressure SEM before use. A bed of the spray dried microparticles or Inhalac 50 lactose was fixed onto a silicon substrate using a thin layer of glue. Force-distance curves were recorded by monitoring the deflections of the cantilever as the probe and sample were brought into contact (approach trace), and then separated (retract trace). Cohesion/adhesion data was obtained from the microparticles and lactose samples consecutively with the same tip.
  • microparticles of the invention may exhibit improved dispersion when formulated as interactive ordered mixtures with excipient particles of lactose as a carrier. In fact, they would be less prone to give rise to the formation of stable agglomerates like common micronised active ingredients.
  • the specific surface area of was determined using nitrogen multipoint BET (Brunauer-Emmet-Teuer) with a TriStar II 3020 instrument.
  • Example 3 Dry powder formulation comprising the microparticles of the invention
  • a hard pellet carrier containing coarse lactose (sieve fraction 212-355 ⁇ ) and co-micronised pre -blend in a ratio of 9: 1 was prepared before manufacture of the formulation according to the teaching of WO 01/78693. Briefly, alpha-lactose monohydrate particles (sieve fraction 212-355 ⁇ ) and a pre -blend fraction of alpha-lactose monohydrate and magnesium stearate were mixed in a ratio of 9: 1.
  • a powder formulation (50 g batch size) containing 1.22% w/w of the microparticles of Example 1 equivalent to 100 ig BDP, 12.5 ig GB, and 6.0 ig FF in 10 mg dose, was prepared in a Turbula mixer. It was prepared by separately weighing out the hard pellet carrier and the microparticles. Half the carrier was added to a stainless steel vessel followed by the microparticles. The remaining carrier was added and the contents mixed at 32 rpm for 90 minutes. The formulation was then sieved using a 500 ⁇ sieve and mixed for a further 30 minutes at 32 rpm. The formulation was stored in an amber glass jar for a minimum of 24 hours at 20°C an 40% relative humidity prior to further analysis.
  • Example 3 The powder formulation of Example 3 was characterized in terms of the uniformity of distribution of the active ingredients and aerosol performances after loading it in the multidose dry powder inhaler described in WO 2004/012801, and quoted hereinafter as NEXThaler ® .
  • Aerosol performances were determined using the Next Generation Impactor (NGI) with a USP induction port and pre-separator containing 15mL 60:40% v/v MeOHiFbO.
  • Critical flow P3/P2 ratio
  • the aerodynamic particle size distribution was based on 5 actuations from the NEXThaler, each sampled into 4 liters of air (equivalent to an inhalation time of 4 s). The device was weighed before and after each actuation to determine the shot weight (mg). A minimum of 1 minute was allowed between consecutive actuations to allow static charge to dissipate.
  • Samples were collected from the NGI using a fixed volume technique.
  • MeOHiEbO 60:40% v/v was dispensed into the induction port (including mouthpiece) ; pre-separator; and each stage using an electronic metering dispenser.
  • the NGI stages (lOmL stages 1-2; 15mL stage 3-MOC) were rocked using a NGI rocker for 3 minutes. All samples were filtered using a 0.2 ⁇ syringe filter before analysis by UPLC-PDA.
  • the delivered dose which is the amount of drug delivered from the device recovered in the all parts of impactor
  • U the fine particle mass
  • FPM fine particle mass
  • FPF fine particle fraction
  • MMAD the MMAD
  • extrafme FPP the percentage of the fine particle dose having a particle size equal to or lower than 2.0 micron.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des particules comprenant une combinaison d'un anticholinergique, d'un agoniste de récepteur bêta2-adrénergique, et d'un corticostéroïde inhalé, un procédé pour leur préparation et leur utilisation pour la prévention et/ou le traitement de maladies respiratoires.
EP15731264.6A 2014-06-09 2015-06-09 Particules d'inhalation comprenant une combinaison d'un anticholinergique, un corticostéroïde et un bêta-adrénergique Active EP3151812B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL15731264T PL3151812T3 (pl) 2014-06-09 2015-06-09 Cząstki do inhalacji obejmujące skojarzenie środka antycholinergicznego, kortykosteroidu i środka beta-adrenergicznego

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14171644 2014-06-09
PCT/EP2015/062764 WO2015189168A1 (fr) 2014-06-09 2015-06-09 Particules d'inhalation comprenant une combinaison d'un anticholinergique, d'un corticostéroïde et d'un bêta-adrénergique

Publications (2)

Publication Number Publication Date
EP3151812A1 true EP3151812A1 (fr) 2017-04-12
EP3151812B1 EP3151812B1 (fr) 2020-04-22

Family

ID=50884789

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15731264.6A Active EP3151812B1 (fr) 2014-06-09 2015-06-09 Particules d'inhalation comprenant une combinaison d'un anticholinergique, un corticostéroïde et un bêta-adrénergique

Country Status (11)

Country Link
US (1) US9554992B2 (fr)
EP (1) EP3151812B1 (fr)
KR (1) KR102285066B1 (fr)
CN (2) CN106456570A (fr)
AR (1) AR100784A1 (fr)
CA (1) CA2951483C (fr)
ES (1) ES2797073T3 (fr)
MX (1) MX369346B (fr)
PL (1) PL3151812T3 (fr)
RU (1) RU2697867C2 (fr)
WO (1) WO2015189168A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022023515A1 (fr) 2020-07-31 2022-02-03 Chemo Research , S.L. Polythérapie destinée à une administration par inhalation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2515855T6 (da) 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
WO2018059390A1 (fr) * 2016-09-29 2018-04-05 广东东阳光药业有限公司 Composition pharmaceutique
US10350164B2 (en) * 2017-05-11 2019-07-16 Chiesi Farmaceutici S.P.A. Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2020020957A1 (fr) * 2018-07-27 2020-01-30 Chiesi Farmaceutici S.P.A. Nouvelles particules de support pour formulations de poudre sèche pour inhalation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
ES2359576T5 (es) 2002-07-31 2020-03-03 Chiesi Farm Spa Inhalador de polvo
EP3090792A1 (fr) 2008-07-18 2016-11-09 Prosonix Limited Procédé pour améliorer la cristallinité
WO2010097188A1 (fr) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
DK2515855T6 (da) 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
NO2560611T3 (fr) * 2010-04-21 2018-06-02
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
ES2867552T3 (es) 2013-07-11 2021-10-20 Chiesi Farm Spa Formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022023515A1 (fr) 2020-07-31 2022-02-03 Chemo Research , S.L. Polythérapie destinée à une administration par inhalation

Also Published As

Publication number Publication date
MX2016016201A (es) 2017-03-08
CA2951483A1 (fr) 2015-12-17
RU2016147888A3 (fr) 2019-01-17
EP3151812B1 (fr) 2020-04-22
KR102285066B1 (ko) 2021-08-05
CN106456570A (zh) 2017-02-22
BR112016026460A2 (pt) 2017-08-15
CN113476429A (zh) 2021-10-08
US9554992B2 (en) 2017-01-31
PL3151812T3 (pl) 2020-10-19
AR100784A1 (es) 2016-11-02
MX369346B (es) 2019-11-06
KR20170017926A (ko) 2017-02-15
RU2016147888A (ru) 2018-07-09
WO2015189168A1 (fr) 2015-12-17
RU2697867C2 (ru) 2019-08-21
BR112016026460A8 (pt) 2021-07-06
ES2797073T3 (es) 2020-12-01
US20150352127A1 (en) 2015-12-10
CA2951483C (fr) 2022-10-25

Similar Documents

Publication Publication Date Title
CA2951483C (fr) Particules d'inhalation comprenant une combinaison d'un anticholinergique, d'un corticosteroide et d'un beta-adrenergique
EP3527197B1 (fr) Formulation de poudre sèche comprenant un corticostéroïde et un béta-adrénergique pour l'administration par inhalation
EP3377108B1 (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
EP3377109B1 (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
US20100269825A1 (en) Inhalation particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1h)-quinolinone and a corticosteroid
US20110097409A1 (en) Particles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone having improved adhesion properties for powder formulations for inhalation
EP3621589B1 (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
EP3621590B1 (fr) Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
BR112016026460B1 (pt) Micropartículas de múltiplos componentes, seu processo de preparação, formulações farmacêuticas e inaladores

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190410

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190920

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20200211

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015051138

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

Ref country code: AT

Ref legal event code: REF

Ref document number: 1259146

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200515

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: CHIESI FARMACEUTICI S.P.A.

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20200401373

Country of ref document: GR

Effective date: 20200716

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200824

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200822

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200722

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2797073

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20201201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015051138

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20210125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200609

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MA

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200422

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230626

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230703

Year of fee payment: 9

Ref country code: CH

Payment date: 20230702

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240627

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240627

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240627

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240626

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240521

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240625

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240521

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240524

Year of fee payment: 10

Ref country code: BE

Payment date: 20240627

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240619

Year of fee payment: 10